Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5010331 | 0.94 | GSR (0.53) | GSRDPP7DPP8DPP9GNAI3 | |
| SCHEMBL1191631 | 0.94 | GSR (0.53) | GSRDPP7DPP8DPP9GNAI3 | |
| SCHEMBL8508704 | 0.93 | GSR (0.46) | GSRDPP7DPP8DPP9GNAI3 | |
| SCHEMBL8950857 | 0.93 | GSR (0.52) | GSRDPP7DPP8DPP9GNAI3 | |
| SCHEMBL8759024 | 0.93 | GSR (0.52) | GSRDPP7DPP8DPP9GNAI3 | |
| Water SCHEMBL5501375 | 0.93 | GSR (0.52) | GSRDPP7DPP8DPP9GNAI3 | |
| SCHEMBL8836488 | 0.93 | GSR (0.52) | GSRDPP7DPP8DPP9GNAI3 | |
| SCHEMBL1065054 | 0.93 | GSR (0.52) | GSRDPP7DPP8DPP9GNAI3 | |
| SCHEMBL8836895 | 0.93 | GSR (0.52) | GSRDPP7DPP8DPP9GNAI3 | |
| SCHEMBL3338905 | 0.91 | GSR (0.50) | GSRDPP7DPP8DPP9GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498289-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2019-06-19 | — | — | EP | claimed |
| EP-2722051-B1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | SEATTLE GENETICS INC (US) | 2018-11-07 | — | — | EP | claimed |
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | claimed |
| EP-2722051-A1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | Seattle Genetics, Inc. (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703714-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-8512707-B2 | Methods of treating drug-resistant cancers | SEATTLE GENETICS, INC. (US) | 2013-08-20 | — | — | US | claimed |
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-01-05 | — | — | US | claimed |
| US-20100260786-A1 | METHODS OF TREATING DRUG-RESISTANT CANCERS | SEATTLE GENETICS, INC. (US) | 2010-10-14 | — | — | US | claimed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | claimed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | claimed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2007137170-A2 | ANTI-GLYPICAN-3 ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007103288-A2 | ENGINEERED ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| WO-2007008848-A2 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| EP-1725249-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seattle Genetics, Inc. (US) | 2006-11-29 | — | — | EP | claimed |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2005-10-27 | — | — | US | claimed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| EP-4727971-A1 | METHODS AND COMPOSITIONS RELATED TO ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ADCS) THAT BIND NECTIN-4 PROTEINS | Adcentrx Therapeutics Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | GSR 2598/4885DPP7 1479/4885DPP8 2211/4885 |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | MMAB, CAD, TRIM59 | GSR 1818/4885DPP7 1058/4885DPP8 1739/4885 |
| US-20100260786-A1 | METHODS OF TREATING DRUG-RESISTANT CANCERS | CD44, TP53, MKI67 | GSR 286/4885DPP7 3138/4885DPP8 3717/4885 |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | CAD, MMAB, AURKC | GSR 2740/4885DPP7 1244/4885DPP8 2327/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | GSR 3711/4885DPP7 208/4885DPP8 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.